Prognosis of patients with HER2+ breast cancer has significantly improved with the use of the monoclonal antibody (mAb) trastuzumab (H), which is capable of blocking HER2 oncogenic signaling and thereby effectively killing HER2+ cancer cells (Hudis 2007). Here, ERBB2 is linked to breast cancer.